Home › Categories › Corporate Reports› 当社子会社の� �んワクチン療� ��に用いる樹状細胞増幅技術� �東アジア並び� ��米国における特許査定のお� �らせ

当社子会社の� �んワクチン療� ��に用いる樹状細胞増幅技術� �東アジア並び� ��米国における特許査定のお� �らせ.pdf

20150325091147_f.pdf

Preview of 当社子会社の� �んワクチン療� ��に用いる樹状細胞増幅技術� �東アジア並び� ��米国における特許査定のお� �らせ

🔗 Source: iromgroup.co.jp

📊 Size: 217 KB

📄 Pages: 2 pages

⬇️ Downloads: 66

Summary

Irom Holdings Co., Ltd. announced that its subsidiary, Dinabec Corporation, has received patent approvals in East Asia and the United States for its dendritic cell expansion technology used in cancer vaccine therapy. The technology allows for the large-scale production of dendritic cells, which are essential for cancer immunotherapy. Dinabec has already granted licenses to companies in Japan and China, and the patent approvals are expected to strengthen the technology's usefulness and contribute to the expansion of the companies' businesses and Dinabec's royalty revenue.

Download File

Description

Irom Holdings Co., Ltd.

Technical Information

File Format: PDF
File Size: 217 KB
Pages: 2
Language: EN
Total Downloads: 66
Last Updated: 2 months ago

Document Overview

This PDF document about 当社子会社の� �んワクチン療� ��に用いる樹状細胞増幅技術� �東アジア並び� ��米国における特許査定のお� �らせ provides comprehensive information and guidance. Whether you're a beginner or advanced user, this resource offers valuable insights into 当社子会社の� �んワクチン療� ��に用いる樹状細胞増幅技術� �東アジア並び� ��米国における特許査定のお� �らせ.